Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
about
Therapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosisDifferential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosisPortal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry.Changing common sense: Anti-platelet/coagulation therapy against cirrhosis.Eptifibatide and Cirrhosis: Rethinking GPIIb-IIIa Inhibitors for Acute Coronary Syndrome in the Setting of Liver DysfunctionDeep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review.Management of coagulation abnormalities in liver disease.The coagulation system in patients with end-stage liver disease.Managing complications in cirrhotic patientsPortal vein thrombosis in cirrhosis.The Best Anticoagulation Strategy for Cirrhotic Patients who Underwent Splenectomy: A Network Meta-Analysis.Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.Role of inferior vena cava filters in transplant patients.Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis.The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis.Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis.Von Willebrand factor deficiency reduces liver fibrosis in mice.Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study.Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician
P2860
Q26774531-92E58D29-33BA-40DF-80E2-BB3084C6EA63Q28539503-2677780C-D450-45AF-8AD1-C18BC590BD4DQ30277075-ABED1B78-EDC2-4A62-9BDE-966F8C0C6013Q30379953-92CC4952-0CB2-4814-9A5A-F0EB59F4EA7CQ33440488-D360F21D-8985-4227-9542-C3EDBEC9013CQ33626817-A671DEC3-4B27-4429-8255-AE64B1080C43Q38223728-44ACA4F0-59D2-4DCA-BBA2-CD13C2EF652BQ38295874-528E2A64-7A56-4A66-B6C0-3461355FC836Q38344890-132BB640-3558-4E10-ACD6-C1860E104991Q38371574-BC1A72BC-983B-4E2F-8A25-F79ED6F5900CQ38693795-B614A19A-7955-473E-92EA-8FF7D455CC45Q38727993-8D7DB01E-2AE0-4610-A2CA-A53F229EAB85Q38995826-02295F65-CDC9-440F-8877-9C1ED6CE927DQ39251865-4ED9628D-1BF1-4007-87EF-150CFD0A2F74Q40410373-5C092909-19AB-4E01-84F6-61899F870A14Q48676397-AF5E173F-9BE6-43EF-8911-231CA4A41C6DQ50206717-7445344D-54B4-409F-8EF4-ADD5275F6E00Q53513180-79434269-4215-40FB-AB06-0234990C031EQ58761721-CDADD729-84D7-4A84-BDCD-A19FBF8B08DD
P2860
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Established and new-generation ...... s - possibilities and caveats.
@ast
Established and new-generation ...... s - possibilities and caveats.
@en
type
label
Established and new-generation ...... s - possibilities and caveats.
@ast
Established and new-generation ...... s - possibilities and caveats.
@en
prefLabel
Established and new-generation ...... s - possibilities and caveats.
@ast
Established and new-generation ...... s - possibilities and caveats.
@en
P2093
P1476
Established and new-generation ...... s - possibilities and caveats.
@en
P2093
Patrick G Northup
Pieter W Kamphuisen
Robert J Porte
P304
P356
10.1016/J.JHEP.2013.03.027
P50
P577
2013-03-30T00:00:00Z